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OBJECTIVE—Accumulating epidemiological evidence suggests
that hypovitaminosis D may be associated with type 2 diabetes
and related metabolic risks. However, prospective data using the
biomarker serum 25-hydroxyvitamin D [25(OH)D] are limited
and therefore examined in the present study.
RESEARCH DESIGN AND METHODS—A total of 524 ran-
domly selected nondiabetic men and women, aged 40–69 years
at baseline, with measurements for serum 25(OH)D and IGF-1 in
the population-based Ely Study, had glycemic status (oral glu-
cose tolerance), lipids, insulin, anthropometry, and blood pres-
sure measured and metabolic syndrome risk (metabolic
syndrome z score) derived at baseline and at 10 years of
follow-up.
RESULTS—Age-adjusted baseline mean serum 25(OH)D was
greater in men (64.5 nmol/l [95% CI 61.2–67.9]) than women (57.2
nmol/l [54.4,60.0]) and varied with season (highest late summer).
Baseline 25(OH)D was associated inversely with 10-year risk of
hyperglycemia (fasting glucose:  0.0023, P  0.019; 2-h
glucose:  0.0097, P  0.006), insulin resistance (fasting
insulin  0.1467, P  0.010; homeostasis model assessment
of insulin resistance [HOMA-IR]:  0.0059, P  0.005), and
metabolic syndrome z score ( 0.0016, P  0.048) after
adjustment for age, sex, smoking, BMI, season, and baseline
value of each metabolic outcome variable. Associations with 2-h
glucose, insulin, and HOMA-IR remained signiﬁcant after further
adjustment for IGF-1, parathyroid hormone, calcium, physical
activity, and social class.
CONCLUSIONS—This prospective study reports inverse asso-
ciations between baseline serum 25(OH)D and future glycemia
and insulin resistance. These associations are potentially impor-
tant in understanding the etiology of abnormal glucose metabo-
lism and warrant investigation in larger, speciﬁcally designed
prospective studies and randomized controlled trials of supple-
mentation. Diabetes 57:2619–2625, 2008
T
hough the most well-known role of vitamin D is
the regulation of calcium absorption and bone
metabolism, it is becoming clear that this hor-
mone has pleiotropic effects with possible roles
in the pathogenesis of cancer (1), cardiovascular disease
(2), multiple sclerosis (3), and type 1 diabetes (4). Recent
epidemiological evidence (5–9) also points to a potential
association of vitamin D insufﬁciency with adverse meta-
bolic risk, including that for type 2 diabetes (10,11). While
the exact mechanisms that underlie the multiple effects of
vitamin D on different tissues are not currently under-
stood, one unifying factor is the expression of vitamin D
receptors (VDRs) in 30 tissues, including pancreatic islet
cells (12). There is some evidence that polymorphisms in
the VDR gene may be associated with insulin resistance,
insulin secretion, and fasting glucose concentrations (13–
16), suggesting that vitamin D is likely to contribute to
glucose metabolism (8). It is also becoming clear that
there are physiological interactions between vitamin D,
IGF-1, and its binding proteins IGFBP-1 and IGFBP-3
(17,18). Variations in circulating IGF-1 and its binding
proteins are associated with variations in glycemia (19)
and may interact with vitamin D status to inﬂuence
metabolic syndrome risk (7).
Epidemiological studies examining vitamin D status and
the risk of hyperglycemia or insulin resistance have thus
far been suggestive of inverse associations but are incon-
clusive. Most studies that have used the biomarker serum
25-hydroxy vitamin D3 [25(OH)D] concentration, generally
recognized as a marker of human vitamin D status, have
been cross-sectional in nature; hence, the temporal se-
quence of associations is unclear. Need et al. previously
reported that lower serum 25(OH)D was associated with
higher fasting glucose throughout the range of serum
25(OH)D measured and most marked when 25(OH)D
levels were 40 nmol/l (20). Ford et al. (6), in the Third
National Health and Nutrition Examination Survey of
8,421 men and women, reported an inverse association
between 25(OH)D and metabolic syndrome risk, particu-
larly for hyperglycemia, hypertriglyceridemia, and abdom-
inal obesity. Hypponen et al. (7) most recently reported in
the 1958 birth cohort study of 6,810 men and women that
higher serum 25(OH)D was associated with lower risk of
metabolic syndrome (odds ratio 0.33 [95% CI 0.26–0.42])
and each of its individual components cross-sectionally,
including an inverse association with A1C level as a
marker of glucose status. They found an interaction be-
tween 25(OH)D and IGF-1 on metabolic risk, such that
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and IGF-1 were highest. To our knowledge, there has only
been one previous prospective study (21) of the associa-
tion between serum 25(OH)D and the risk of type 2
diabetes, but the inverse association was attenuated and
made nonsigniﬁcant after adjustment for confounders.
There are no prospective studies, to the best of our
knowledge, of the association between serum 25(OH)D
and future continuous distribution of glycemic status or
insulin resistance. Several studies (11,22,23) have exam-
ined the association of diabetes or metabolic syndrome
risk with dietary and/or supplemental vitamin D intake,
but this represents only a small proportion of vitamin D
available in humans, especially in the U.K., where few
foods are vitamin D fortiﬁed (e.g., margarine) or naturally
rich in vitamin D (e.g., egg yolk and oily ﬁsh). The main
source of vitamin D is from sunlight exposure of the skin,
in which a narrow band of ultraviolet-B radiation converts
its prehormone, endogenously, into vitamin D3 in the skin,
while liver, kidneys, and other activating tissues then
hydroxylate it to form 25(OH)D and 1,25-dihydroxyvitamin
D3 (calcitriol), respectively. There is general agreement
that serum 25(OH)D concentrations best reﬂect vitamin D
repletion or “status,” current deﬁnitions being suggested
to be “sufﬁciency” (concentrations 75 nmol/l or 30 g/l),
“hypovitaminosis D” (75 nmol/l or 30 g/l), “insufﬁ-
ciency” (50 nmol/l or 20 g/l) (12), and classical
“deﬁciency” (25 nmol/l).
The aim of our study was to investigate the prospective
association between serum 25(OH)D concentration and
markers of metabolic risk, including glucose, insulin,
insulin resistance, and a continuous metabolic syndrome
risk z score. We further wanted to test whether any
associations observed were independent of a comprehen-
sive range of potential confounding or effect-modifying
factors, including circulating IGF-1 or its binding proteins.
RESEARCH DESIGN AND METHODS
The participants in this study are a subset of the Ely Study (Cambridgeshire,
U.K.), which was established in 1990 as a prospective study; detailed meth-
odology has been described previously (24,25). In brief, from a sampling frame
of all adults free of known diabetes and registered with a single practice
serving Ely, 1,122 European-origin adults, aged 40–69 years, were randomly
selected (response rate 74%). The baseline examination took place between
1990 and 1992. Among those who were biochemically nondiabetic (n  1,040)
at baseline (26), follow-up examination occurred at a median of 4.5 years
(when n  912 attended) and again at 10 years (when n  683 attended). Of
683 with baseline and 10-year follow-up data, 524 participants had complete
data for this analysis after exclusions [n  5 excluded with elevated plasma
creatinine 150 mol/l, n  126 missing blood samples for serum 25(OH)D
and IGF-1 assays, and n  28 for other missing variables] and formed the
present study population. All participants gave written informed consent, and
the study was approved by the local research ethics committee.
Measurements. At both the baseline (1990–1992) and the 10-year (2000–
2003) health check visits, participants attended in the morning after an
overnight fast. We performed anthropometric measurements to standard
protocol (25), including waist circumference (cm), weight (kg), and height
(m), and calculated BMI (weight in kilograms divided by the square of height
in meters [kg/m
2]). Blood pressure was measured using a standard protocol
while seated (25). Venous plasma glucose was measured both fasting and 120
min after a 75-g glucose load (oral glucose tolerance test) and analyzed in
fresh samples using a hexokinase assay on blood collected into ﬂuoridated
tubes. All samples were cooled on ice, centrifuged into plasma/serum aliquots
onsite, and stored at 70°C within4ho fcollection. Biochemical assays were
carried out using frozen aliquots for lipids (fasting triglyceride and HDL
cholesterol) and fasting insulin. Plasma insulin was measured using two-site
immunoassays with either
125I or alkaline phosphatase labels and triglycerides
with the RA1000 (Bayer Diagnostics, Suffolk, U.K.), using a standard auto-
mated enzymatic method. All samples (baseline and 10-year follow-up) were
handled in the same manner and analyzed at Addenbrooke’s Hospital clinical
chemistry laboratory.
At baseline, fasting serum 25(OH)D concentration was measured by
radioimmunoassay using acetonitrile extracts of serum. Intact serum parathy-
roid hormone (PTH) was measured using a two-site immunoradiometric assay
with an NH2-terminal monoclonal antibody as capture. Total serum calcium
concentration was measured using a modiﬁed ortho-cresolphthalein com-
pexone reaction with 8-quinolinol to reduce magnesium interference, while
serum albumin, measured with an adapted bromocresol purple dye–binding
method, was used to calculate corrected calcium. Serum creatinine was
assayed using the alkaline picrate Jaffe reaction. Fasting plasma concentra-
tions of IGF-1, IGFBP-1, and IGFBP-3 (IGF binding proteins) were measured
by previously reported antibody-based assays (27). All interassay coefﬁcients
of variation were 15%. Additionally, at baseline, information was collected
by questionnaire on smoking habits, physical activity, and employment (25).
We categorized these variables as never, ex-smoker, or current smoker and
manual or nonmanual occupational social class, respectively. Physical activity
was described as a continuously distributed physical activity score obtained
from the modiﬁed Paffenbarger questionnaire, from which we computed
estimates of energy expended in speciﬁc activities as the multiple of reported
frequency and duration by the average energy cost of that activity from the
Ainsworth energy expenditure compendium. The energy cost of activities is
measured in metabolic equivalents (METs), which is a means of expressing
the energy expenditure of that activity relative to that of resting. The units of
the resulting summary score summated over all reported activities are MET
hours per day (28).
Statistical methods. From the date of blood draw, we derived the season of
measurement of serum 25(OH)D (April through September coded as spring/
summer; October through March as autumn/winter). As sex-speciﬁc associa-
tions with outcomes were similar, and there was no interaction between sex
and 25(OH)D, analyses were pooled for men and women. Four categories of
25(OH)D (created to reﬂect deﬁciency [25 nmol/l], insufﬁciency [25–49.9
nmol/l], hypovitaminosis but not insufﬁciency [50–74.9 nmol/l], and sufﬁciency
[75 nmol/l]) were used to examine the distribution of baseline parameters
adjusted for age and sex. We tested differences in proportions using 
2 tests
and linear trends for continuous traits across 25(OH)D categories using
generalized linear models. For nonnormally distributed variables (fasting
insulin, triglycerides, IGFBP-1, PTH, and homeostasis model assessment of
insulin resistance [HOMA-IR]) we applied logarithmic transformations and
examined geometric means and 95% CIs.
The outcomes were continuous quantitative metabolic traits, including
fasting glucose, 2-h glucose, and fasting insulin. Additionally, we calculated a
marker of insulin resistance in the form of the HOMA-IR as follows: ([fasting
insulin  fasting glucose]/22.5) (29). We also derived a continuous metabolic
syndrome risk z score as the mean of the following ﬁve sex-speciﬁc standard-
ized continuous indexes of obesity (BMI 	 waist circumference/2), hyperten-
sion (systolic blood pressure 	 diastolic blood pressure/2), insulin resistance
(fasting insulin), hyperglycemia (2-h plasma glucose), and dyslipidemia (in-
verted fasting HDL 	 fasting triglycerides/2) (30). We did not study the
outcome of diabetes incidence a priori, as we had only 54 events by 10 years
of follow-up among this cohort.
We used multiple linear regression to assess the relationship between
baseline circulating 25(OH)D (continuous) and metabolic status (continuous)
at the 10-year follow-up. We adjusted for the potential confounding variables,
as determined a priori. Three models were constructed. Model 1 was adjusted
for age, sex, smoking status, season, BMI, and baseline status of the metabolic
parameter being assessed as the outcome variable in the linear regression (for
instance adjusting for fasting glucose at baseline when examining fasting
glucose at the 10-year follow-up). Model 2 was additionally adjusted for PTH
level, corrected calcium, and IGF-1. Model 3 was additionally adjusted for
physical activity score and for social class. The variables age, BMI, waist
circumference, and physical activity score were entered in all models as
continuous variables, while family history, sex, season, and smoking status
were used as categorical variables. We tested for statistical interaction of
25(OH)D with BMI, IGF-1, and the IGF-1 binding proteins IGFBP-1 and
IGFBP-3 by using product terms and likelihood ratio tests. All statistical
analyses were performed using Stata/SE 9.2 (Stata, College Station, TX). All P
values were based on two-sided tests. The cutoff for statistical signiﬁcance
was 0.05.
RESULTS
Among 524 initially nondiabetic participants with com-
plete data at baseline and 10-year follow-up, there were
214 men and 310 women, mean (
SD) age 52.9 
 7.7 years
at baseline. Serum 25(OH)D concentration was higher in
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 23.4
nmol/l; P  0.001); the age- and sex-adjusted mean
25(OH)D concentration was 60.2 
 25.3 nmol/l. Serum
25(OH)D was strongly related to the season in which it
was measured, with the lowest levels found in early spring
and highest in late summer in both men and women (Fig.
1). For most (n  10) months of the year, serum 25(OH)D
concentrations were 75 nmol/l, and for 4 months of the
year, the mean concentration was 50 nmol/l (i.e., in the
hypovitaminosis D and insufﬁciency range, respectively).
Twenty-nine participants (72% women) were vitamin D
deﬁcient [25(OH)D 25 nmol/l].
Table 1 shows that at baseline, across categories of
increasing serum 25(OH)D, there was a signiﬁcantly
greater proportion of men, and both systolic and diastolic
blood pressure were lower. BMI was not signiﬁcantly
different across vitamin D categories, while waist circum-
ference was lowest in the highest category of 25(OH)D.
With increasing 25(OH)D, there was a signiﬁcant decrease
in fasting glucose, fasting insulin, HOMA-IR, and metabolic
syndrome risk z score, while there was an increase in
IGF-1 levels and in both its binding proteins. Notably,
serum PTH was signiﬁcantly lower and serum calcium
higher across increasing categories of 25(OH)D.
Table 2 shows that baseline 25(OH)D was signiﬁcantly
inversely associated with 10-year risk of increase in fasting
glucose, 2-h glucose, fasting insulin, HOMA-IR, and meta-
bolic syndrome risk z score in analyses adjusted for age,
sex, smoking, BMI, season, and for the baseline status of
the metabolic outcome variable (model 1). We did not ﬁnd
any signiﬁcant association with lipids, blood pressure, or
waist circumference, suggesting that the association with
FIG. 1. The distribution of serum 25(OH)D by month in men (solid
line) and women (broken line) in the Ely study. Vertical lines are the
95% CIs around the mean values at each month point. Month 1
represents January, while month 12 represents December.
TABLE 1
Age- and sex-adjusted baseline characteristics by categories of baseline 25(OH)D: the Ely Study 1990–2000
25(OH)D categories at baseline
P value 25 nmol/l 25–49.9 nmol/l 50–74.9 nmol/l 75 nmol/l
n 29 155 219 121
Age (years) 50 (47.2–52.8) 52 (50.8–53.2) 53.5 (52.5–54.5) 53.7 (52.3–55.1) 0.007
Women 21 (72.4) 106 (68.4) 128 (58.5) 55 (45.5) 0.001
Family history of diabetes 5 (17.2) 27 (17.4) 35 (16.0) 14 (11.6) 0.578
Smoking
Former 10 (34.5) 32 (20.6) 66 (30.1) 44 (36.4)
Current 4 (13.8) 32 (20.6) 33 (15.1) 25 (20.7) 0.058
Social class (manual) 13 (44.8) 55 (35.5) 78 (35.6) 51 (42.1) 0.446
BMI (kg/m
2) 24.6 (23.3–25.9) 25.7 (25.1–26.3) 25.5 (25–25.9) 25.0 (24.3–25.6) 0.449
Waist circumference (cm) 80.9 (77.6–84.2) 83.9 (82.5–85.4) 81.9 (80.7–83.1) 80.1 (78.5–81.7) 0.010
Systolic blood pressure
(mmHg) 130.7 (124.9–136.5) 129.4 (126.8–131.9) 127.3 (125.2–129.5) 122.8 (119.8–125.74 0.0008
Diastolic blood pressure
(mmHg) 78.8 (75.2–82.5) 79.1 (77.5–80.7) 77.8 (76.5–79.2) 74.73 (72.85–76.61) 0.002
Total MET hours per day
score 12.5 (8.4–16.6) 12.2 (10.5–13.9) 14 (12.5–15.4) 14.4 (12.5–16.4) 0.090
IGF-1 148.6 (129–168.2) 147.5 (139–156) 165.9 (158.8–173) 161.7 (152–171.3) 0.013
IGFBP-1* 20.7 (16.3–26.4) 22.5 (20.2–25) 24.2 (22.1–26.4) 25.2 (22.4–28.4) 0.075
IGFBP-3 3.81 (3.53–4.1) 3.81 (3.69–3.94) 3.94 (3.84–4.05) 3.98 (3.84–4.13) 0.059
Fasting glucose (mmol/l) 5.72 (5.55–5.9) 5.69 (5.62–5.77) 5.66 (5.6–5.73) 5.57 (5.49–5.66) 0.036
2-h glucose (mmol/l) 5.85 (5.32–6.37) 6.16 (5.93–6.39) 6.02 (5.83–6.21) 6.14 (5.89–6.4) 0.754
Fasting plasma insulin
(pmol/l)* 45.1 (37.4–54.4) 39.8 (36.7–43.2) 37.9 (35.4–40.6) 33.5 (30.6–36.8) 0.001
Total cholesterol (mmol/l) 6.43 (6.01–6.85) 6.4 (6.22–6.59) 6.46 (6.3–6.61) 6.52 (6.31–6.72) 0.466
HDL cholesterol (mmol/l) 1.5 (1.37–1.62) 1.43 (1.38–1.49) 1.52 (1.48–1.57) 1.51 (1.45–1.57) 0.098
Fasting triglyceride
(mmol/l)* 1.16 (0.99–1.37) 1.17 (1.09–1.25) 1.1 (1.03–1.16) 1.12 (1.03–1.21) 0.343
HOMA-IR index* 1.64 (1.35–2.00) 1.44 (1.32–1.57) 1.37 (1.27–1.47) 1.19 (1.08–1.31) 0.0007
Metabolic syndrome risk
z score 0.04 (0.18 to 0.25) 0.11 (0.02–0.21) 0.01 (0.09 to 0.07) 0.13 (0.24 to 0.02) 0.003
PTH (g/l)* 37.7 (32.6–43.5) 30.2 (28.4–32.2) 26.6 (25.2–28.0) 24.3 (22.7–26.1) 1.5E-09
Calcium (mmol/l) 2.12 (2.08–2.16) 2.11 (2.09–2.12) 2.13 (2.12–2.15) 2.15 (2.13–2.17) 0.008
Data are n (%) or arithmetic or *geometric mean (95% CI), adjusted for age and sex (except age, adjusted for sex only). P values are the test
for proportions for categorical variables or the test for linear trend for continuous traits.
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and insulin component. Additionally, adjusting for IGF-1,
PTH, and calcium level (model 2), or including additional
adjustment for physical activity score and social class
(model 3), made no material difference to the associations
between 25(OH)D and 2-h glucose, fasting insulin, and
HOMA-IR, but the associations were attenuated, not abol-
ished, for fasting glucose and metabolic syndrome risk z
score. Per 25 nmol/l increase in serum 25(OH)D at base-
line [which is equivalent to 1 SD of the 25(OH)D distribu-
tion], there was a decrease in 10-year follow-up of 0.05
mmol/l in fasting glucose, 0.25 mmol/l in 2-h glucose, 4.2
pmol/l in fasting insulin, 0.16 units in HOMA-IR, and 0.05
units in metabolic syndrome risk z score, in adjusted
analyses.
We found no signiﬁcant association between baseline
IGF-1 and 10-year continuously distributed quantitative
metabolic trait outcomes. There was no interaction be-
tween baseline 25(OH)D and IGF-1 on any of the meta-
bolic outcomes. When testing for the effect of IGF-1
binding proteins, we found a signiﬁcant interaction be-
tween 25(OH)D and IGFBP-1 for the 10-year outcomes of
fasting glucose (P  0.0005) and 2-h glucose (P  0.029).
There was also a signiﬁcant interaction between 25(OH)D
and BMI on the risk for 10-year HOMA-IR (P  0.011) but
not for any other outcome. Figure 2 shows how the inverse
association between follow-up fasting and 2-h glucose was
modiﬁed in participants with values of IGFBP-1 below and
above the median (Fig. 2A–D). Thus, the decreasing fast-
ing or 2-h glucose levels across increasing categories of
25(OH)D was signiﬁcant among those with below, but not
above, median IGFBP-1. Figure 2 combines data for the
two lowest categories of 25(OH)D because of small num-
bers (n  29) in the vitamin D deﬁcient group, but the
results are identical in magnitude and direction if four
categories of vitamin D (as in Table 1) are used instead of
three (as in Fig. 2).
DISCUSSION
We report, using the Ely population-based prospective
study, that baseline vitamin D status [25(OH)D concentra-
tion] in nondiabetic participants is inversely associated
with glucose status, insulin resistance, and metabolic
syndrome risk at the 10-year follow-up. Among these
individuals, higher baseline 25(OH)D was associated with
signiﬁcant decreases in 10-year follow-up 2-h glucose,
fasting insulin, HOMA index, and metabolic syndrome risk
z score in analyses adjusted for a comprehensive range of
potential confounders and mediators. These ﬁndings ap-
pear to be novel, with no previous study we can ﬁnd of
prospective associations between baseline serum
25(OH)D and future risk of disturbed glucose metabolism
or metabolic syndrome risk as assessed using continuous
quantitative metabolic traits.
Our ﬁndings conﬁrm previously reported cross-sectional
observations. For instance, among 8,421 U.S. adults, those
with metabolic syndrome had lower 25(OH)D concentra-
tions (67.1 nmol/l) than those without (75.9 nmol/l) (6).
Among 6,810 Caucasians in the 1958 birth cohort, aged 45
years, serum 25(OH)D was associated inversely with met-
abolic syndrome risk cross-sectionally, with independent
associations for high A1C, blood pressure, and triglycer-
ides after adjustment (7). Although we found an inverse
association between baseline serum 25(OH)D and incident
continuous metabolic syndrome risk z score, we did not
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as for blood pressure. The association of blood markers of
vitamin D with blood pressure or hypertension is complex,
and there are inconsistent ﬁndings ranging from no asso-
ciation to inverse or positive association (previously dis-
cussed by Scragg et al. [31]). A recent study (32) of the
association of plasma 25(OH)D with incident hypertension
reported an inverse association, but study limitations
included using predicted vitamin D levels and self-re-
ported hypertension rather than actual measurement in
some of the included cohorts in that study. Notably, we did
report a signiﬁcant inverse association between serum
25(OH)D and systolic and diastolic blood pressure at
baseline but did not ﬁnd this prospectively. Further study
of such associations is warranted in larger cohorts.
While there was evidence of interaction between
25(OH)D and IGF-1 on metabolic syndrome risk in a
previous study [metabolic syndrome risk being least when
both 25(OH)D and IGF-1 were highest] (7), we found no
such interaction for 10 year risk of metabolic syndrome
measured as a continuous risk z score, or for any individ-
ual metabolic component. We did ﬁnd signiﬁcant interac-
tion between baseline IGFBP-1 and 25(OH)D on fasting
and 2-h glucose at 10 years when signiﬁcantly lower
glycemia with increasing 25(OH)D was found in those with
low, but not high, IGFBP-1. Notably, in the Ely cohort we
have previously reported interaction between IGF-1 and
IGFBP-1 on 4.5-year follow-up 2-h glucose concentration;
those with lower, but not higher, IGFBP-1 having decreas-
ing concentrations of 2-h glucose with increasing tertiles
of baseline IGF-1 (19). Since IGF-1 increases with
25(OH)D at baseline in our cohort, as in the 1958 birth
cohort (7), this may explain our 4.5-year ﬁndings. Our
present 10-year follow-up data suggest, as previously re-
ported (17,18), that biological interactions between
IGFBP-1 axis and 25(OH)D are potentially important in
glucose homeostasis long term and that IGF-1 axis and
vitamin D axis interactions should be studied further. For
example, IGFBP-1 concentrations may reﬂect variations in
insulin secretion or hepatic insulin sensitivity, important
components in glucose regulation (33).
Studies are emerging on vitamin D supplementation and
glucometabolic risk. A post hoc analysis within a trial
designed for bone health reported that calcium and vita-
min D supplementation had no effect on fasting glucose or
HOMA-IR over 3 years in 314 individuals (34). This study
did, however, ﬁnd that among those with impaired fasting
glucose (but not with normoglycemia), there was a modest
FIG. 2. Association between baseline serum 25(OH)D and 10-year follow-up fasting glucose (A and B) and 2-h glucose (C and D). A and C: The
association in the entire cohort. B and D: The association was modiﬁed in participants with below and above median values of IGFBP-1. B: ,
lower IGFBP-1, P  0.0028; f, higher IGFBP-1, P  0.6802; IGFBP-1–vitamin D interaction, P  0.00047. C: , lower IGFBP-1, P  0.0031; f,
higher IGFBP-1, P  0.4935; IGFBP-1–vitamin D interaction, P  0.0286. The MRC Ely Study 1990–2000.
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HOMA-IR (P for treatment vs. placebo, 0.042 and 0.031,
respectively) (34). That study measured serum 25(OH)D in
a subset, which increased with intervention, but did not
report on its associations with the metabolic outcomes.
Since dietary intake, including supplementation, provides
little vitamin D and sunlight exposure providing the major
source through skin synthesis, it is important that further
studies include assessment of individual vitamin D status
[serum 25(OH)D concentration]. A recent larger, clinical
trial (23) of vitamin D plus calcium supplementation (400
IU and 1,000 mg, respectively, daily versus placebo) in
34,000 nondiabetic women (the Women’s Health Initia-
tive Study) also included 2,020 women for whom repeat
measures of fasting glucose and fasting insulin were
available. There was no signiﬁcant effect of supplementa-
tion on these metabolic parameters at 3 or 6 years of
follow-up. Notably, there was also no signiﬁcant associa-
tion with incident diabetes risk over 7 years (hazard ratio
1.01 [95% CI 0.94–1.10], with 2,291 cases of incident type 2
diabetes). However, the independent effect of vitamin D
could not be assessed as the supplementation was in
combination with calcium, and, as the authors suggest, the
dose of vitamin D given (400 IU) was modest and likely to
be inadequate (23). Furthermore, since dietary intake is a
poor source of vitamin D, compared with sunlight-induced
endogenous skin production, such studies require serum
25(OH)D data as well, in at least a representative sub-
sample.
What mechanisms may explain the associations of lower
serum vitamin D status with risks of greater levels of
glycemia and insulin resistance we have observed? Possi-
bilities include direct effects of vitamin D on pancreatic
-cell secretory function through their nuclear VDRs,
effects on insulin sensitivity through stimulation of insulin
receptor expression regulation of intracellular calcium
since an effector part of the vitamin D pathway is the
vitamin D–dependent calcium-binding protein required for
postinsulin receptor effects in insulin-responsive tissues,
and also indirect effects through inﬂammatory processes
(35,36). Furthermore, inadequate vitamin D usually leads
to increased serum PTH, which in turn has been found to
be inversely associated with insulin sensitivity in healthy
adults (37). Finally, VDR gene polymorphisms have been
associated with variation in insulin secretion among a
British Bangladeshi South Asian population (14,16) and in
glycemia among community-based older American adults
(38), and other gene polymorphisms may affect glucose
metabolism, as recently reviewed (39).
Limitations of our study include that it was of modest
size, and the included cohort with complete data com-
prised 50% of the initial cohort, which could have
potentially biased our results. However, when comparing
baseline characteristics among included and excluded
participants, included participants tended to be younger
and healthier (lower blood pressure, lower BMI, lower
fasting and 2-h glucose, and lower fasting insulin) than
nonparticipants. This is in keeping with the frequently
observed “healthy participant effect” in epidemiological
studies, which, if anything, would lead to a more conser-
vative estimate of association. On an a priori basis, we did
not study the association with clinical outcomes such as
diabetes, as we had inadequate statistical power (20%
power with 54 incident events of diabetes) but restricted
our outcomes to continuous quantitative traits. While we
could study association with future glucose concentration,
we could not examine association with A1C, a longer-term
marker of glycemic status, as we did not measure A1C at
baseline in our study. While we measured baseline serum
25(OH)D, we do not have data for sun exposure (including
holidays in the sun), for supplement use, nor any interval
measures of vitamin D status. We have, however, previ-
ously found remarkably close correlations between mea-
sures of vitamin D status for each month over 2–3 years in
British South Asians from east London (Boucher BJ,
Mannan N, and Noonan K, unpublished data). Though
stability of vitamin D status across the years is unknown
for European Caucasians, as in our study, it is likely to be
similar in view of the regularity of seasonal variations over
time. Our ﬁndings, valid within a population of European
Caucasians, cannot be extrapolated to other ethnic
groups, given the previously reported heterogeneity by
ethnicity (10). Despite these limitations, strengths of our
study include the population-based nature of the study; the
use of a direct, objective measure of vitamin D status,
rather than relying on self-reported vitamin D intake or
sunlight exposure; and the comprehensive range of
quantitative metabolic markers (at baseline and at 10-
year follow-up), including glucose measurement with
oral glucose tolerance tests, fasting insulin, and derived
markers of insulin resistance (HOMA-IR) and a continuous
metabolic syndrome risk z score. Furthermore, we have
been able to adjust our analyses for a robust range of
potential confounders and mediators, including PTH and
calcium status (rarely included in other studies of such
associations), as well as for smoking, physical activity,
season, obesity, social class, age, and sex, which increases
conﬁdence in the independence of the observed associa-
tions. However, we acknowledge that residual confound-
ing from measured and unmeasured factors cannot be
excluded. Our data also demonstrate that mean serum
25(OH)D concentrations were 75 nmol/l (hypovitamino-
sis D) for 10 months of the year and 50 nmol/l for 4
months of the year (vitamin D insufﬁciency) in this cohort.
There is evidence of a high prevalence of hypovitaminosis
D worldwide (40), and our data are indicative of the
chronically inadequate vitamin D repletion common to
northern latitudes (41). This widespread problem, com-
bined with our ﬁnding that higher vitamin D status
[25(OH)D] may have a beneﬁcial effect on future gluco-
metabolic risk proﬁle, raises a matter of public health
importance deserving serious further investigation.
In conclusion, we have demonstrated inverse associa-
tions of baseline serum vitamin D concentration with
future glucose levels and insulin resistance in a prospec-
tive population-based study, such that higher baseline
vitamin D is associated with signiﬁcantly lower future
glucose, insulin, and HOMA-IR. These associations are
independent of risk factors and potential confounders and
are potentially important in understanding the etiology of
metabolic disturbances associated with type 2 diabetes.
Despite mounting evidence linking inadequate vitamin D
repletion with abnormalities of glucose and insulin metab-
olism, the role of vitamin D is not fully understood and
deserves further investigation in both larger, speciﬁcally
designed prospective studies and with randomized con-
trolled trials of supplementation. Demonstration of a
causal role for hypovitaminosis D in these disorders would
lead to new targets for efforts to prevent type 2 diabetes at
the population level and, possibly, for its treatment.
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